Profil bibliographique

Richard Riedel

Informations fournies par OpenAlex. Research Africa ne déduit ni nationalité, ni poste, ni coordonnées personnelles.

78Publications signalées

1293Citations signalées

4Affiliations récentes

Institutions déclarées

Düsseldorf University Hospital Integrated Oncology (United States)University Hospital Cologne Heinrich Heine University Düsseldorf

Domaines associés

Lung Cancer Treatments and MutationsLung Cancer Research StudiesCancer Genomics and DiagnosticsLung Cancer Diagnosis and TreatmentColorectal Cancer Treatments and Studies

Publications récentes

Accès ouvert 2026 article

Rationale and Study Design of the GUIDANCE trial: A Multicenter Phase II Trial of Maintenance Durvalumab and Olaparib After Standard Fist Line Treatment (Carboplatin/Cisplatin, Etoposide, and Durvalumab) in HRD Positive Extensive Disease (ED) Small-cell Lung Cancer (SCLC) (AIO-TRK-0124/ass)

Richard Riedel, Malte Verheyen, Sebastian Michels, Lea Ruge et autres

0 citationsClinical Lung Cancer

Accès ouvert 2026 supplementary-materials

Supplementary Figure S1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

0 citations

Accès ouvert 2026 supplementary-materials

Supplementary Figure S3 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

0 citations

Accès ouvert 2026 other

Data from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

0 citations

Accès ouvert 2026 supplementary-materials

Supplementary Data 1 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

0 citations

Accès ouvert 2026 supplementary-materials

Supplementary Figure S2 from Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

0 citations

2026 article

Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS Q61 Mutations to Assess Therapeutic Responses

Lea Ruge, Felix John, Malte Verheyen, Richard Riedel et autres

0 citationsClinical Cancer Research

Accès ouvert 2026 article

194eP Large-panel diagnostics detect heterogeneous alterations in acquired resistance to targeted NSCLC treatment

S. Stilianakis, Richard Riedel, E.L. Buchmeier, S. Hahn et autres

0 citationsESMO Open

Accès ouvert 2026 article

62P Clinical and molecular characteristics of NRAS mutations in advanced non-small cell lung cancer (NSCLC)

J. Anselm, Anna Rasokat, P. Christopoulos, A. Stenzinger et autres

0 citationsESMO Open

2025 article

Molecular and Clinical Characteristics of Patients with Non–Small Cell Lung Cancer Harboring KRAS G12V Mutations

Felix John, Lea Ruge, Malte Verheyen, Heather Scharpenseel et autres

2 citationsClinical Cancer Research

Accès ouvert 2025 preprint

CTNNB1 ( β -catenin) mutations in NSCLC: clinicogenomic characteristics, prognostic value and implications for therapy

Moritz Glaser, Cornelia von Levetzow, Anna Rasokat, Darinka Prang et autres

0 citationsmedRxiv

Accès ouvert 2025 article

MET-Driven Resistance to Sotorasib in KRAS G12C–Mutant NSCLC and Response to Combined KRAS and MET Inhibition

Richard Riedel, Lea Ruge, Malte Verheyen, Felix John et autres

1 citationJTO Clinical and Research Reports

Profil ORCID Notice OpenAlex

BNTIC News n’est pas le producteur de ces données. Métadonnées interrogées à la demande auprès de OpenAlex (CC0). Sources et limites.